|1.||Leonardi, A: 4 articles (12/2007 - 01/2000)|
|2.||Ciprandi, G: 3 articles (01/2003 - 01/2000)|
|3.||Secchi, A: 3 articles (06/2001 - 01/2000)|
|4.||Sarret, Philippe: 2 articles (06/2014 - 09/2013)|
|5.||Allaire, C: 2 articles (09/2012 - 03/2005)|
|6.||Uchida, Eiji: 2 articles (08/2010 - 06/2006)|
|7.||Kamei, Chiaki: 2 articles (04/2009 - 03/2005)|
|8.||Colin, J: 2 articles (12/2008 - 03/2004)|
|9.||Uchio, Eiichi: 2 articles (09/2008 - 09/2006)|
|10.||Fukagawa, Kazumi: 2 articles (09/2006 - 06/2006)|
|1.||Allergic Conjunctivitis (Giant Papillary Conjunctivitis)
01/01/1992 - "In guinea-pigs orally and topically administered levocabastine are remarkably effective against allergic conjunctivitis."
06/01/2006 - "The results indicate that 0.025% levocabastine ophthalmic suspension is effective and safe in the treatment of allergic conjunctivitis with a duration of action of at least 4 h."
09/01/1994 - "The objective of this study was to evaluate the efficacy of 0.05% levocabastine, a new antihistamine formulated for ophthalmic use, compared with the placebo vehicle for the treatment of allergic conjunctivitis induced by ocular allergen challenge. "
09/01/2012 - "To evaluate the safety and efficacy of preservative-free levocabastine 0.05 % ophthalmic solution compared to placebo (vehicle) and to preserved levocabastine 0.05 % ophthalmic suspension in the prevention of allergic conjunctivitis induced by a conjunctival provocation test. "
09/01/2006 - "The early efficacy of topical levocabastine in patients with allergic conjunctivitis."
06/01/2006 - "Levocabastine showed prolonged efficacy in inhibiting itching (0.42 +/- 0.12 vs 0.94 +/- 0.17, P < 0.0002) and redness (1.04 +/- 0.18 vs 1.42 +/- 0.22, P < 0.01) of the conjunctiva upon the rechallenge test. "
06/01/2006 - "The mean itching score in the levocabastine-treated group was 0.08 +/- 0.06, which was significantly lower than the mean score of 1.98 +/- 0.16 in the vehicle group (P < 0.0001). "
12/01/2000 - "Emadastine 0.05% was statistically significantly more effective than levocabastine 0.05% in reducing ocular itching after conjunctival allergen challenge in both the 10-minute and the 2-hour challenge (P <.05). "
09/01/1994 - "These results demonstrate that levocabastine, currently the only ophthalmic antihistamine available that is not combined with a vasoconstrictor, is efficacious in the inhibition of itching, as well as all of the allergic signs of a vascular origin, with a duration of action of at least 4 hours. "
10/01/1988 - "Levocabastine prevented both redness and itching. "
03/01/1998 - "In conclusion this study shows that a levocabastine pretreatment before an NPT in patients with grass pollen rhinitis, outside the grass pollen season, induces a significant increase in the cumulative allergen doses (administered by the NPT) which provoked rhinitis symptoms but is not able to demonstrate any significant reduction in the ECP concentrations of the NLF."
06/01/1996 - "[Efficacy of levocabastine in perennial rhinitis]."
10/01/2015 - "To test the hypothesis that intranasal levocabastine (LEVO) may provide benefits as a oncedaily treatment in allergic rhinitis (AR), this non-inferiority study compared the effect at steady state of once- and twice-daily dosing with LEVO on allergen-induced nasal symptoms in AR patients. "
09/01/1996 - "A total of 22 asymptomatic patients with a documented history of allergic rhinitis participated in this single-centre, double-blind, randomized, placebo-controlled, cross-over trial undertaken to assess the efficacy and tolerability of levocabastine nasal spray (0.5 mg/ml) in the prevention of allergen-induced nasal symptoms. "
05/01/1991 - "Twenty-three clinical trials have been performed with levocabastine nasal spray in 1363 patients with allergic rhinitis. "
|4.||Seasonal Allergic Rhinitis (Hay Fever)
09/01/1995 - "In this international, multicentre, randomized, double-blind, parallel-group, placebo-controlled trial 262 patients participated to assess the efficacy and tolerability of levocabastine nasal spray in the treatment of seasonal allergic rhinitis. "
09/01/1995 - "Intranasal levocabastine for the treatment of seasonal allergic rhinitis: a multicentre, double-blind, placebo-controlled trial."
01/01/1999 - "Efficacy and safety of levocabastine nasal spray for seasonal allergic rhinitis."
12/01/1994 - "[Usefulness of levocabastine for topical use in seasonal allergic rhinitis]."
10/01/1987 - "Sixty-six patients with seasonal allergic rhinitis due to birch pollens, participated in an efficacy evaluation of topically applied, nasal and ocular, levocabastine, a highly selective H1 antagonist. "
10/01/1996 - "Levocabastine is a selective topical H1 antagonist, effective in the treatment of seasonal allergic rhinitis and conjunctivitis. "
05/01/1998 - "The group of 32 children aged from 5 to 11 years suffering from seasonal allergic rhinitis and conjunctivitis were treated by means of levocabastine applied topically by 20 days during the period of natural exposition to grass pollen. "
12/01/1995 - "However, the results available to date suggest that the topical formulations of levocabastine are a valuable treatment option in patients with allergic rhinitis and/or conjunctivitis."
01/01/1987 - "The local administration of levocabastine might be useful in allergic rhinitis and conjunctivitis."
05/01/1993 - "Levocabastine is well-tolerated and at least as effective as sodium cromoglycate in the treatment of pollen-provoked conjunctivitis."
|1.||Ophthalmic Solutions (Eye Drops)
|2.||Cromolyn Sodium (Cromoglicic Acid)
|3.||Histamine (Histamine Dihydrochloride)
|7.||Histamine Antagonists (Antihistamines)
|3.||Renal Dialysis (Hemodialysis)